Description of Invention: This invention describes a gene that codes for a human topoisomerase that exclusively acts on mitochondrial DNA, and is the first described mitochondrial topoisomerase. Since a number of diseases are caused by mitochondrial malfunction, this gene could form the basis of a number of different therapies. For instance, mitochondrial malfunctions could lead to disturbances in energy metabolism and programmed cell death (apoptosis). This mitochondrial gene product could thus lead to new diagnoses and therapies centered on apoptosis, which is a critical event in cancer and autoimmune disorders.
In addition to the gene sequence, the patent application covers the encoded protein, protein fragments, monoclonal and polyclonal antibodies, and methods to alter the level of this gene's expression. Also included in the claims are methods to identify activators or inhibitors of the topoisomerase enzyme. NIH invites commercial partners to apply for either an exclusive or non-exclusive license to this technology. We also invite companies who may be interested in commercializing the topoisomerase or the antibodies for research reagent use.
Portfolios: Cancer Cancer - Therapeutics Cancer - Research Materials Infectious Diseases Infectious Diseases - Therapeutics Internal Medicine Internal Medicine - Research Materials
For Additional Information Please Contact: Betty Tong Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-594-6565 Fax: 301-402-0220